News Releases
Filter by Year
September 18, 2021
BEVERLY, Mass. – September 17, 2021 – LexaGene Holdings, Inc. (OTCQB: LXXGF; TSX-V: LXG) ("LexaGene" or "the Company"), a  molecular diagnostics company developing automated rapid polymerase…

September 16, 2021
BEVERLY, Mass. – September 16, 2021 – LexaGene Holdings, Inc. (OTCQB: LXXGF; TSX-V: LXG) ("LexaGene" or "the Company"), a  molecular diagnostics company developing automated rapid polymerase…

September 7, 2021
MiQLab detected both bacterial strains in polymicrobial samples in ~2 hours. Culture and Sensitivity Testing (C&ST) failed to detect the minor pathogen population in individual…

September 6, 2021
BEVERLY, Mass. – September 3, 2021 – LexaGene Holdings, Inc. ("the Company"), (OTCQB: LXXGF; TSX-V: LXG), a molecular diagnostics company that develops fully automated rapid…

September 3, 2021
On-site demonstrations will spotlight how MiQLab’s next-generation technology is advancing veterinary PCR diagnostic testing. September 7-9, WVC 93rd Annual Conference, Las Vegas, NV September 12-14,…

August 12, 2021
First point-of-need PCR system capable of using conventional probe-based chemistry or inexpensive, rapidly available SYBR Green chemistry. BEVERLY, Mass. – Aug 12, 2021 – LexaGene Holdings,…

July 20, 2021
Mycoplasmas are thought to contaminate 15-80% of cell cultures worldwide. MiQLab rapidly detected 100% of the tested mycoplasma samples within two hours, with no false…

July 14, 2021
Announces participation in national investor conference and webcast on Thursday, July 15 BEVERLY, Mass. USA – July 14, 2021 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG)…

July 7, 2021
New panel offers extensive improvements for pathogen identification and drug resistance gene testing Increases targeted pathogens from 7 to 10 (140% of the original) Increases…

July 2, 2021
BEVERLY, Mass. USA – July 2, 2021 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen…

1 2 3 4 5 15

For Marketing inquiries, please email:

info@lexagene.com

800-215-1824